Psychosocial Interventions prolong lives in women with Coronary Artery Disease –trial evidence Kristina Orth-Gomér, MD, PhD Karolinska institutet, Stockholm.

Slides:



Advertisements
Similar presentations
Depression, Vital Exhaustion and recurrent heart disease.
Advertisements

Summary Prepared by Melvyn Rubenfire, MD
Depression, Vital Exhaustion and recurrent heart disease.
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
1 Adapting to Life’s Challenges Individuals within Communities within Environments Dr Brian M. Hughes, PhD Director.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Stress and Health. Psychological Factors Affecting a Medical Condition A general medical condition Psychological factors adversely affect the general.
Psychosocial Risk Factors for Cardiovascular Disease Nathan D. Wong, PhD.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Orlando, Florida – October 7, 2011 Cardiac Rehab: Improving Outcomes One Step at a Time Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine.
The Practice of Clinical Health Psychology Robin Perkins, Ph.D. Clinical Psychologist Archbold Integrative Medicine Center.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
CHAPTER 24: Converging Issues in Heart Disease, Stroke, and Alzheimer’s Disease in Women.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
RISK FACTOR FOR CORONARY ARTERY DISEASE
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Modern Management of Cholesterol in the High-Risk Patient.
European Society of Cardiology Cardiovascular diseases in women.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Secondary Prevention & Cardiac Rehabilitation Malcolm Walker Consultant Cardiologist UCLH & the Heart Hospital, London.
Primordial, primary, secondary, and tertiary prevention stages for global vascular risk. R. Sacco: Stroke, Volume 38(6).June
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Cardiac Rehabilitation 2011 Update for Primary Care Providers Douglass A Morrison, MD, PhD Cardiac Rehabilitation, Medical Director Yakima Regional and.
Depressive Disorders and Cardiovascular Medicine Lawson Wulsin, MD Copyright © World Psychiatric Association.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Depression and cardiovascular disease an epidemiological perspective Nicole Vogelzangs Psychiatry / EMGO institute, VU University Medical Center.
Better Patient Adherence: Why patients don’t adhere and what we can do about it (maybe) Frank Doyle, PhD RCSI Royal College of Surgeons in Ireland Coláiste.
Spencer Nance PSY 328/01 March 11, 2015 Dr. Gordon Cappelletty.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
META-ANALYSIS OF THE EFFECTIVENESS OF PSYCHOLOGICAL SUPPORT ON THE IMPROVEMENT OF CORONARY HEART DISEASE PATIENTS’ OUTCOMES Aggelopoulou Z 1,, Mantzorou.
How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.
Atherosclerotic Cardiovascular Heart Disease in Women
Vital exhaustion predicts the progression of myocardial infarction-
Women and Cardiovascular Disease
Antonio Coca, MD, PhD, FRCP, FESC
for Overall Prognosis Workshop Cochrane Colloquium, Seoul
Prof. Dr. med. Sigmund Silber Cardiology Practice and Hospital
The role of unknown risk factors in coronary heart disease
The Importance of Adequately Powered Studies
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Clinical need for determination of vulnerable plaques
The IDEAL Study Reference
Κολπικη μαρμαρυγη σε ασθενεις με αποφρακτικη υπνικη απνοια
How to Promote Women Awareness to Heart Disease and the Role for Women
AIM HIGH Niacin plus Statin to prevent vascular events
HDL cholesterol and cardiovascular risk Epidemiological evidence
FATS- Familial Atherosclerosis Treatment Study
Heart Health & Diabetes
Vincent M. Figueredo, MD, FACC, FAHA, FASE 
Laura Donato [Mentor: Wendy Bjerke] College of Health Professions
Jeff Macemon Waikato Cardiothoracic Unit
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
Section 5: Intervention and drug therapy
Type 2 diabetes: Overlap of clinical conditions
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Exercise-Based Cardiac Rehabilitation and Improvements in Cardiorespiratory Fitness: Implications Regarding Patient Benefit  Barry A. Franklin, PhD  Mayo.
Prevention & the Healthcare Crisis 2004
Global Registry of Acute Coronary Events: GRACE
Potential mechanisms whereby statins may reduce the risk of stroke
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Cardiovascular Epidemiology and Epidemiological Modelling
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Psychosocial Interventions prolong lives in women with Coronary Artery Disease –trial evidence Kristina Orth-Gomér, MD, PhD Karolinska institutet, Stockholm ESC Congress Barcelona September 1st, 2014

Women´s hearts 1.Women die from heart disease as often as men 2.Women get heart disease ten years later than men 3.Younger women with CHD – worse prognosis than men

Psychosocial risk factors verified and supported by ”European Guidelines of cardiovascular disease prevention” (European Heart J 2003) Low SES Stress Lack of social support Depression Anxiety Hostility

Behavioral model in cardiovascular disease

Progression of atherosclerosis by Marital & Work Stress Mean Segment Diameter Change (mm) Wang, Theorell, Orth Gomer, et al, 2004

Progression of atherosclerosis by Exhaustion Zimmermann-Viehoff, Orth-Gomér K et al, Psychosomatic Medicine (2013)

FemCorRisk findings psychosocial predictors of CHD in women - Low education, low occupation, low SES Wamala et al Am J Public Health,1999., Marital Stress Orth-Gomér et al, JAMA 2000, Job stress Wamala et al,Soc Sci Med 2000, 481 – Poor sleep quality Leineweber et al J Psychosom Res Social isolation Horsten et al Eur Heart J 2000, 21, Depression Horsten et al Eur Heart J 2000, , Zimmerman et al Eur J cardiovascular Prev, Vital exhaustion Zimmerman, Orth-Gomér et al, Psychsom Med 2013

In 2003 ESC Guidelines summarized ….Evidence for Psychosocial Factors In 2004 Interheart estimated Psychosocial Factors to contribute 1/3 of etiologic fraction

Psychosocial stress Cognitive behavior therapy to reduce stress - Randomized Controlled Trials : ENRICHD multicenter US men, women patients (n=3000)neg / pos substudy SWITCHD Stockholm women patients pos SUPRIM Uppsala patients pos

RCT´s in coronary heart disease since 2003 Endpoints depressive cardiac events mortality symptoms Therapy __________________________________________________________________________ SAD HEART Antidepressants CREATE Interpersonal therapy and antidepressants Long term follow up: ENRICHD CBT SWICHD CBT SUPRIM CBT _________________________________________________________________________ (Linden, Psychosomatic Medicine 2013)

ENRICHD – Effects of CBT to mortality and MI Writing Committee for the ENRICHD investigators, JAMA 2003;289: OR 1.01 (0.86 – 1.08)

ENRICHD - secondary analysis: differential effects by gender and ethnicity Schneiderman et al., Psychosom Med 2004;66: white men: cardiac death, non fatal MI OR , p=.004

Objective To examine whether stress reduction may improve prognosis in patients with CHD Orth-Gom é r,K, Schneiderman,N,Wang H, et al Circulation, Quality & Outcome, 2009

Study group 237 Stockholm women < 75 years, mean age 62 Hospitalized for acute myocardial infarction or cardiological intervention Randomized to CBT + regular care/ regular cardiologcal care Adding CBT to regular care may reduce recurrent events?

Cognitive behavioral group based Stress reduction - based on Type A intervention in San Fransisco, modified for Swedish women - twenty 2-hour sessions, 4-6 patients/group session 1-10 weekly, session monthly - delivered by cardiology research nurses with special interest and training in behavioral/psychosocial medicine - education, discussions, and home assignments.

Stress reduction balancing work and family demands solving interpersonal conflicts, male/female role conflicts Counteracting -stress - depression - isolation - low self-esteem

Changes in Daily stress behaviour in intervention and controlgroup (p< ) treatment time interaction p<.0001

Heading

Clinical predictors of mortality in women with CHD

Behavioral change in survivors Interv Controls p __________________________________________ Quit smoking 38% 43% ns Improved diet 88% 78% ns Increased exercise 40% 47% ns __________________________________________

Behavioral change in survivors Interv. Controls p Improved sleep 23% 5% Worsened sleep 13% 27% Sleep quality (1-4) 2.5(1.0) 2.1(1.2) p=.05

the group was a life line was allowed to dwell on heart disease felt comparisonship felt support Worried less felt social cohesion developed more patience could talk about things one don’t really want to talk about learnt not to get hurt not afraid any more increased self esteem courage to say no stonger psyche become aware become more egocentered not as angy as previously enjoys life more courage to talk in the group has fewer obligations

Heading Mortality by statin use and CBT

Psychophysiological Pathways Autonomic Cardiac Imbalance - Decreased Heart Rate Variability, Increased Heart Rate Neuroendocrine/metabolic pathways -Dyslipidemia, Insuline Resistance, Metabolic syndrome Prothrombotic/inflammatory pathways - Fibrinogen, Von Willebrand, Factor VII, PAI - I, hs CRP…..

Conclusions Prognosis of the heart disease improved by adding CBT to usual care Mechanisms -stress reduction - unhealthy habits improved -autonomic dysfunction improved -better adherence to cardiologic treatment

Conclusion in women with CHD… harmful marital stress worsened prognosis marital stress accelerated coronary atherosclerosis progression protective cognitive behavioral intervention reduced all cause mortality a happy marriage - deceleration of coronary atherosclerosis

Thank you for listening